Home  /  Resource Library  /  Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults

Results of a study investigating CAR-T axicabtagene ciloleucel for treatment of relapsed indolent lymphomas.